CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
Revenue
CRISPR Therapeutics AG
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Revenue
$37.3m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Revenue
CHf27.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Molecular Partners AG
SIX:MOLN
|
Revenue
CHf5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Revenue
CHf208.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Revenue
CHf92.9m
|
CAGR 3-Years
89%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
Revenue
CHf113.6m
|
CAGR 3-Years
113%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
Revenue Breakdown
Breakdown by Geography
CRISPR Therapeutics AG
Breakdown by Segments
CRISPR Therapeutics AG
|
Total Revenue:
37.3m
USD
|
|
Collaboration Revenue:
35m
USD
|
|
Grant:
2.3m
USD
|
CRISPR Therapeutics AG
Glance View
CRISPR Therapeutics AG is at the forefront of revolutionizing modern medicine through gene-editing technology. Founded on the groundbreaking research of CRISPR-Cas9, a tool that allows scientists to precisely alter an organism’s DNA, the company has swiftly emerged as a leader in the biotech arena. Situated in Switzerland, with significant operations in the United States, CRISPR Therapeutics aims to translate this cutting-edge science into transformative therapies. Its portfolio highlights collaborative efforts with other industry giants to develop treatments for serious genetic diseases, such as its flagship program targeting sickle cell disease and beta-thalassemia. By leveraging its proprietary CRISPR platform, the company focuses on developing gene-based medicines that address the root causes of illnesses, marking a departure from traditional symptom management to potentially groundbreaking cures. The business model of CRISPR Therapeutics is both innovative and strategic. Monetization is achieved through a blend of partnerships, licensing agreements, and direct therapeutic development. The company collaborates with various pharmaceutical entities, creating a network of shared knowledge and resources that accelerates the commercialization of therapies. These alliances facilitate shared risk and reward, allowing CRISPR Therapeutics to generate revenue while advancing its research and development pipeline. Moreover, the successful progression of any internally-developed therapies into approved treatments has the potential to unlock significant financial returns, both from sales and potential royalties. True to its visionary roots, CRISPR Therapeutics not only pursues immediate financial success but also seeks to redefine the landscape of genetic medicine with the long-term goal of delivering curative treatments for numerous genetic conditions.
See Also
What is CRISPR Therapeutics AG's Revenue?
Revenue
37.3m
USD
Based on the financial report for Dec 31, 2024, CRISPR Therapeutics AG's Revenue amounts to 37.3m USD.
What is CRISPR Therapeutics AG's Revenue growth rate?
Revenue CAGR 5Y
-34%
Over the last year, the Revenue growth was -90%. The average annual Revenue growth rates for CRISPR Therapeutics AG have been -66% over the past three years , -34% over the past five years .
You don't have any saved screeners yet